Veterinary monoclonal antibodies
Monoclonal antibody therapies for animals, such as Zoetis' Cytopoint (authorised 2017) and Librela (2020), used as alternatives to glucocorticoids or antihistamines for allergic skin disease and chronic pain.
1 · What it gives
Veterinary monoclonal antibodies are immunoglobulins with defined specificity from a single clone, made by recombinant DNA, hybridoma or other techniques. They act as alternatives to traditional treatments such as glucocorticoids or antihistamines for allergic skin disease or chronic pain. They are at commercial scale: Cytopoint received marketing authorisation in 2017 and Librela in 2020.
2 · What it replaces 6
3 · How to implement 3 steps
- 1Identify candidatesIdentify antibody candidates.
- 2Cell line and cultureSelect a high-producing cell line and develop cell culture.
- 3Purify and formulatePurify and formulate the product.
4 · Who delivers
Matched suppliers (matched automatically)
| Lootah BioFuels | United Arab Emirates | Producer | active |
| Agolin | Switzerland | Producer | active |
| Shield Biological Projects | Israel | Producer | active |
| Mycotech Lab (MYCL) | Indonesia | Producer | active |
| BioHAYAT | Turkey | Research / RTO | active |
| EGAVET | Egypt | Research / RTO | active |
| Liselo Labs | South Africa | Research / RTO | active |
| Vland Biotech 蔚蓝生物 (SSE 603739) | China | Research / RTO | active |
| CellX | China | Producer | active |
| Competitive Green Technologies | Canada | Research / RTO | active |
| EcoFix Kenya Ltd (EFK) | Kenya | Producer | active |
| Ecovative | United States | Producer | active |
Leading companies and institutes (from the brief)
Zoetis is named as a prominent developer and provider. Others are matched by the portal under Veterinary.
5 · Rules & route to market
per shipment (veterinary and phytosanitary control)
Information, not legal advice — confirm the procedure for your product. (2026-10-06)
United States
In the US the FDA or the USDA regulates them, depending on the therapeutic indication.
European Union
In the EU the EMA regulates veterinary monoclonal antibodies.
China
The sources reviewed on 2026-10-16 identified no China regulator or standard specific to this technology. Treat the route as case-by-case and ask for a check.
6 · Money: tenders & grants
No open tender or grant matched right now.
7 · Tech stack & innovations
Main risks from the sources: immunogenicity, off-target specificity, and regulatory and economic hurdles around biosimilar pathways.
Sources 5
- Ema.europa.eu — www.ema.europa.eu 2026-10-16
- Zoetis.com — www.zoetis.com 2026-10-16
- Doi.org — doi.org 2026-10-16
- Mabion.eu — www.mabion.eu 2026-10-16
- News.zoetis.com — news.zoetis.com 2026-10-16